Andreas L. Birkenfeld

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark et al. · New England Journal of Medicine · 2019 · 1.9K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.8K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

Patrick M. O’Neil, Andreas L. Birkenfeld, Barbara McGowan et al. · The Lancet · 2018 · 804 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea

Julio Rosenstock, Andreas L. Birkenfeld, Thalia Marie Blicher et al. · JAMA · 2019 · 398 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes

Róbert Wágner, Martin Heni, Ádám G. Tabák et al. · Nature Medicine · 2021 · 380 citations · Full text

Medicine, Biomedical Sciences, Endocrinology +14